

## NEW DEVELOPMENT IN CANCER BIOLOGICS

ROBINSON COLLEGE, CAMBRIDGE, UK  
SEPTEMBER 3-4, 2012

World Biopharm Forum welcomes you to join the international scientists from academia and industries who will focus on presenting some of the most cutting edge advances in research and development of new cancer biologics and bringing to the forefront the pace of their clinical applications

### Marketing and Sponsoring

If you are interested in marketing and sponsoring please contact  
[gsub@subramanian.org.uk](mailto:gsub@subramanian.org.uk)

### DAY 1

12.50 Welcome *Dr G Subramanian*

### Cancer Stem Cells *Jennie Mather, chair*

**13.00** Metastasis is...when cancer stem Cells find their niches.  
*Dr. Ilaria Malanchi, London Research Institute, London, UK.*

**13.20** A New cancer stem cell model recapitulating colon cancer differentiation provides evidence for intestine stem cell origin of cancer stem cells.  
*Dr. Jennie Mather, VP Stem Cells, Macrogenics Inc., USA*

**13.40** Modelling the breast cancer metastatic niche  
*Dr. Gabriela Dontu, Clinical Reader, King's College, London, UK.*

**14.00** Targeting Notch and Wnt in cancer.  
*Dr Austin Gurney, VP, Oncomed, USA.*



**14.20** Breast Cancer stem cells: Regulation and role in therapeutic resistance.  
*Dr. Rob Clarke, PICR, Manchester, UK.*

### Cancer Immunotherapy *Robert Wilkinson, chair*

**14.40** Monoclonal T cells receptor therapy of cancer.  
*Professor Hans Stauss, Head of Department of Immunology, Royal Free Hospital, UCL London, UK.*

**15.00** Engineering T cells for cancer therapy: Lessons from preclinical work and early clinical trial.  
*Professor Robert Hawkins, Director of Medical Oncology, PICR, Manchester, UK.*

**15.20** Simulating anti-cancer immunity with agnostic antibodies.  
*Professor Martin J. Glennie University of Southampton. UK.*

**15.40** Development of antibodies and bispecific targeting B7-H3 a novel target on solid tumour.  
*Dr. Paul Moore. VP, Cell Biology and Immunology, Macrogenics. USA.*

### 16.00 REFRESHMENTS

**16.20** Recruit Tand Abs: Tetravalent bifunctional antibodies for immunotherapy of cancer  
*Dr. Eugene Zhukovsky, CSO, Affimed Therapeutics. Germany.*

**16.40** The rapidly changing therapeutic paradigm for the treatment of melanoma.  
*Dr. Brian Huber, VP and Managing Director, Quintiles, USA.*

**17.00** Harnessing immunotherapy.  
*Dr. Robert Wilkinson, Director of Biology, Oncology, Medimmune, Cambridge, UK*

### Armed Antibodies for Imaging and Therapy I *John Lambert, chair*

**17.20** Antibody drug conjugates (ADC'S): realising the promise of antibody-directed targeting in Cancer patients.  
*Dr. John Lambert., Executive VP and CSO, Immunogen Inc., USA.*

**17.40** Antibody-Drug Conjugates at Bayer.  
*Dr. Rene Hoet. Bayer Pharma AG, Germany.*

**18.00** New approaches to Molecularly targeted radiotherapy.  
*Professor Katherine Vallis, Gray Institute for Radiation oncology and Biology University of Oxford, UK.*

**18.20** Armed antibodies in preclinical and clinical development at Philogen.  
*Dr. Sarah Wulhfard, Philochem AG., Switzerland.*

### DAY 2

### Armed Antibodies for Imaging and therapy II *Professor Anna Wu, chair*

**08.00** A system for greatly improving the affordability of anti-cancer antibodies  
*Dr. Daryl Fernandes, CEO Ludger Ltd., Oxford, UK.*

**08.20** Engineered antibody fragments for molecular targeting and imaging of cancer.  
*Professor Anna Wu, Crump Institute of Molecular Imaging, UCLA, USA.*

**08.40** Nuclear and optical imaging of monoclonal antibodies: Non invasive immunohistochemistry in vivo.  
*Professor Guus van Dongen GAMS, VUMC, The Netherlands.*

## **Enhancing biological activity of antibodies**

*Professor Thomas Valerius, chair*

**09.00** Increasing the therapeutic efficacy of epidermal growth factor receptor(EGFR) antibodies.

*Professor Thomas Valerius, Med2, University of Kiel, Germany.*

**09.20** Cracking the C-mat code: strictly antagonistic mabs blocking HGF dependent and independent signalling.

*Dr Karen Silence arGEN-BVBA, Belgium,*

**09.40** FC-mediated effector functions of therapeutic antibodies.

*Dr. Marije Overdijk, Scientist, Genmab, The Netherlands.*

**10.00** Therapeutic induction of a B-cell inhibitory pathway using bispecific DART proteins.

*Dr. Ezio Bonvini, Senior VP, Research, MacroGenics Inc., USA.*

## **10.20 REFRESHMENTS**

### **Bispecifics and beyond**

*Professor Terence Rabbitts, chair*

**11.00** Generation Bispecific antibodies via controlled Fab-arm Exchange.

*Dr. Aran F. Labrijn, Sr. Scientist, Genmab, The Netherlands.*

**11.20**  $\kappa\lambda$ -Bodies: fully human bispecific antibodies for tumour targeting.

*Dr Nicolas Fischer Novimmune SA. Switzerland*

**11.40** Optimisation of DART for different applications.

*Dr. Syd Johnson, VP. Antibody Engineering, MacroGenics Inc., USA.*

**12.00** Agnostic biologics from multivalent scaffold proteins.

*Dr. Jeffrey Swers, Medimmune, Inc., USA*

**12.20** Shrinking of antibodies for intracellular function.

*Professor Terence H. Rabbitts, Weatherall Institute of Molecular Medicine. University of Oxford, UK.*

### **Novel Agents, Novel Targets**

*Professor Marie-Paule Lefranc, chair*

**14.00** IMGT® databases and tools for IG, TR and MH sequences and structures.

*Professor Marie-Paule Lefranc, CNRS, Montpellier University, Montpellier, France.*

**14.20** Human Primary B Lymphocytes for the rapid high throughput discovery of Native Therapeutic Monoclonal Antibodies

*Dr. Nicola Beltraminelli, Director of Antibody Discovery.. Vivalis, France*

**14.40** Generation of Fully human therapeutic antibodies against GPCR targets.

*Dr. Sergeji Kipyronov, VP discovery, Affitech AS, Norway,*

**15.00** Small activating RNA's and Diabetes.

*Professor Naggy Habib. Imperial college, Health care trust, London, UK.*

**15.20** Nanomedicines as tools in cancer therapy.

*Dr. Andreas Schatzlein, Reader, The School of Pharmacy. London, UK.*

**15.40 CONCLUSION** *Dr.G.Subramanian.*

## **REGISTRATION**

Please complete the registration form in BLOCK LETTERS and post it with full remittance to: Dr. G. Subramanian, 44 Oaken Grove, Maidenhead, Berkshire, SL6 6HH UK. Your reservation will be confirmed upon receipt of your full payment.

Full Name:

.....

Job Title: .....

Organisation: .....

Address:

.....

.....

Postcode: .....

Country: .....

Tel: .....

Fax: .....

Email: .....

Any special Requirement (Dietary):

.....

.....

### **Registration fees:**

Full Attendance including all meals and accommodation: £700

Attendance with no accommodation £575

### **Method of Payment:**

Cheques payable to **Dr. G. Subramanian** in Pound Sterling only and drawn on a UK based bank. For other payment method please visit our website at

[www.subramanian.org.uk](http://www.subramanian.org.uk).

### **Cancellation:**

Should you be unable to attend, a substitute delegate is welcomed at no extra charge.